PROMETHEUS BIOSCIENCES INC (RXDX) 108.68 +0.25 (+0.23%)
108.68 +0.25 (+0.23%)
US74349U1088 - Common Stock - After market: 108.68 0 (0%)
Notable Thursday Option Activity: RXDX, BLND, CLFD
Prometheus Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
Prometheus Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision...
Noteworthy Monday Option Activity: APO, SMCI, RXDX
Investors Grab RXDX Even Cheaper Than Its Secondary Stock Offering
Is Prometheus Biosciences a Good Stock to Buy Right Now?
This biotech stock just jumped over 180% in a single day, and investors want to know if there could be more big gains ahead.
Prometheus Biosciences, Inc. Announces Pricing of Public Upsized $500 Million Offering of Common Stock
Prometheus Biosciences, Inc. Announces Pricing of Public Upsized $500 Million Offering of Common Stock
SAN DIEGO, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision...
Prometheus Biosciences Larger Than S&P 500 Component Ralph Lauren
Why Shares of Prometheus Biosciences Are Soaring This Week
The clinical-stage biotech that specializes in IBD therapies announced positive news regarding two trials for its lead therapy.
Biotechs Race for New Treatments as Breast Cancer Therapeutics Market Could Reach $15 Billion by 2028
EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:GILD),(NYSE:BMY),(NASDAQ:RXDS),(NASDAQ:RNAZ) EQNX::TICKER_END
Biotechs Race for New Treatments as Breast Cancer Therapeutics Market Could Reach $15 Billion by 2028
/PRNewswire/ -- FinancialNewsMedia.com News Commentary - According to a report from Global Market Insights the Breast Cancer Therapeutics Market size, which...
Hot Stocks: CVNA crashes more than 40%; ASO jumps on earnings; SWBI drops; RXDX skyrockets
CVNA plunges more than 40%. ASO climbs on earnings news. SWBI declines on quarterly results. RXDX skyrockets on clinical data.
Prometheus Biosciences, Inc. Announces Proposed Public Offering of Common Stock
Prometheus Biosciences, Inc. Announces Proposed Public Offering of Common Stock
SAN DIEGO, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision...
PINS Stock Alert: What to Know as Pinterest and Elliott Strike a Deal
Pinterest (PINS) stock is on the move Wednesday as investors react to an agreement with Elliott Investment Management L.P.
Why Is Prometheus Biosciences (RXDX) Stock Up 175% Today?
Prometheus Biosciences (NASDAQ:RXDX) stock is rocketing higher on Wednesday after reporting results from two Phase 2 clinical trials.
Prometheus Biosciences Catapults 176% On Promising Results In Irritable Bowel Disease
Prometheus Biosciences made waves Wednesday in irritable bowel disease.
These 2 Nasdaq Stocks Knocked It Out of the Park Wednesday
Even as broader markets fell, these companies announced great news.
Prometheus stock surges 190% as inflammatory bowel disease drug shows efficacy in trials
Prometheus Biosciences (RXDX) said its medicine PRA023 showed strong efficacy and favorable safety in two mid stage trials in patients with ulcerative colitis ((UC)) and Crohn’s...